Diabetic Retinopathy - Drug Pipeline Landscape, 2023

Diabetic Retinopathy - Drug Pipeline Landscape, 2023

Diabetic retinopathy is a censorious medical disorder that affects the eyes due to inefficient insulin level in the blood of the patient. A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow resulting in cloudy or blurred vision. There are two types of diabetic retinopathy non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

A high sugar level in the blood causes blockage of the retina's small blood capillaries and impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy.

Symptoms of diabetic retinopathy are blurred vision, dark or empty spots in the vision, fluctuating vision, poor colour identification and vision loss.

Diabetic retinopathy is diagnosed by a comprehensive dilated eye exam and Fluorescein angiography.

Diabetic retinopathy is treated by diet modifications and drugs like insulin vascular endothelial growth factor inhibitors and laser treatment, eye surgery.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Retinopathy treatment such as KSI-301, LY-09004, RTH258 and others. Key players involved in the development of therapies to treat Diabetic Retinopathy are Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Hengenix Biotech Inc, OcuTerra Therapeutics Inc and others. Seven drugs are under late-stage Phase III clinical trials and sixteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

In October 2022, OcuTerra published safety and biological activity data of OTT166 from phase 1b study in diabetic eye disease.

Report Highlights

Global Insight Service's, Diabetic Retinopathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Retinopathy pipeline drugs. This report covers detailed insights on Diabetic Retinopathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Retinopathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.